Preferred Label : Anti-MET x MET Antibody Drug Conjugate REGN5093-M114;
NCIt synonyms : MET x MET ADC REGN5093-M114; Anti-MET ADC REGN5093-M114; Anti-MET Antibody-drug Conjugate REGN5093-M114; ADC REGN5093-M114; Antibody-drug Conjugate REGN5093-M114; Anti-MET x MET ADC REGN5093-M114;
NCIt definition : An antibody-drug conjugate (ADC) consisting of REGN5093, a biparatopic monoclonal
antibody that targets two different epitopes of the human tumor-associated antigen
(TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), and conjugated, via a
protease cleavable linker, to the cytotoxic maytansine derivative M24, with potential
antineoplastic activity. Upon administration of anti-MET x MET ADC REGN5093-M114,
the REGN5093 moiety targets and binds to two different, non-overlapping epitopes on
MET expressed on the tumor cell surface. After antibody-antigen interaction followed
by internalization and protease cleavage, the maytansine M24 moiety binds to tubulin,
inhibits microtubule assembly, and induces microtubule disassembly. This leads to
a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing
MET. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various
solid tumor cell types where it is involved in epithelial-mesenchymal transition;
it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.;
Molecule name : REGN5093-M114; REGN5093-M 114;
NCI Metathesaurus CUI : CL1664825;
Origin ID : C182004;
UMLS CUI : C5557413;
Semantic type(s)
- concept_is_in_subset
- has_target
